- Home
- LXRX vs AURA Comparison
LXRX vs AURA Comparison
Compare LXRX & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXRX
- AURA
- Stock Information
- Founded
- LXRX 1995
- AURA 2007
- Country
- LXRX United States
- AURA United States
- Employees
- LXRX N/A
- AURA N/A
- Industry
- LXRX Biotechnology: Pharmaceutical Preparations
- AURA Biotechnology: Pharmaceutical Preparations
- Sector
- LXRX Health Care
- AURA Health Care
- Exchange
- LXRX Nasdaq
- AURA Nasdaq
- Market Cap
- LXRX 650.7M
- AURA 572.0M
- IPO Year
- LXRX 2000
- AURA 2021
- Fundamental
- Price
- LXRX $0.98
- AURA $9.47
- Analyst Decision
- LXRX Buy
- AURA Strong Buy
- Analyst Count
- LXRX 2
- AURA 4
- Target Price
- LXRX $6.00
- AURA $23.00
- AVG Volume (30 Days)
- LXRX 4.3M
- AURA 184.2K
- Earning Date
- LXRX 11-12-2024
- AURA 11-12-2024
- Dividend Yield
- LXRX N/A
- AURA N/A
- EPS Growth
- LXRX N/A
- AURA N/A
- EPS
- LXRX N/A
- AURA N/A
- Revenue
- LXRX $5,229,000.00
- AURA N/A
- Revenue This Year
- LXRX $1,212.46
- AURA N/A
- Revenue Next Year
- LXRX $219.10
- AURA N/A
- P/E Ratio
- LXRX N/A
- AURA N/A
- Revenue Growth
- LXRX 886.60
- AURA N/A
- 52 Week Low
- LXRX $0.97
- AURA $6.63
- 52 Week High
- LXRX $3.73
- AURA $12.38
- Technical
- Relative Strength Index (RSI)
- LXRX 25.78
- AURA 39.43
- Support Level
- LXRX $1.01
- AURA $10.48
- Resistance Level
- LXRX $1.35
- AURA $11.29
- Average True Range (ATR)
- LXRX 0.12
- AURA 0.56
- MACD
- LXRX -0.06
- AURA -0.18
- Stochastic Oscillator
- LXRX 0.43
- AURA 2.67
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.